Remember
 
+
 
+
 Do You Know the Most Important and Timely Stock Plays During the Trading Week? View Our Power Rankings.
 
Teambronx Followed anonusers19 hours ago
Teambronx Followed MarkNewYork19 hours ago
Teambronx Followed russurban19 hours ago
anonusers Placed a 'Buy' Sentiment on CETY3 days ago
anonusers Placed a 'Buy' Sentiment on SRMX4 days ago
anonusers Placed a 'Buy' Sentiment on AIMTMore than a week ago
Bullseye27 Followed messageboardMore than a week ago
Bullseye27 Followed trendingstocksMore than a week ago
Bullseye27 Followed specstreamtrendingMore than a week ago
 
@EricawCruzz just joined SpeculatingStocks.
 
Most Discussed Stocks through Posts and Reactions on SpeculatingStocks  UNVC  •  VXRT  •  OSTK  •  NFLX  •  BB  •  TWTR  •  CGC  •  ARCI  •  LULU  •  SNAP  Reserve Investor Relations Services for OTC Stocks at goalx.org

Fighting Cancer Stocks & ETFs, Headlines, and Posts Bucket Watchlist of Fighting Cancer Stocks, ETFs, Headlines and Posts

Types of Stocks and ETFs: cancer, oncology, pharma, etc.















Watchlist of Stocks and ETFs Based on Theme: Companies Related to Fighting Cancer.

Generated with SpeculatingStocks Stock Theme Analytics Algorithmâ„¢ - More Bucket Watchlists of Stocks.

Important Note: Most of the stocks and ETFs in this list directly relate to fighting cancer; however, a few may just somewhat depend and/or be indirectly related to fighting cancer. As always complete your own due diligence.


Fighting Cancer Stocks & ETFs


Symbol
Company / ETF Name
Market Cap





















































386.488M
















108.54M




















198.107B
























244.572B






























































132.409B




























































54.418B






















































124.047B











Recent Fighting Cancer Headlines





Recent Fighting Cancer Posts (Pulses)




01/-0/2019: $LOXO Loxo Oncology leading oncology stocks higher after being acquired by Eli Lilly (LLY) for $8B at a 68% premium. -- Go to this Pulse Post



01/-0/2019: $LOXO Loxo Oncology up 65% leading oncology stocks higher after being acquired by Eli Lilly (LLY) for $8B in cash ($235 per share) at a 68% premium. -- Go to this Pulse Post



01/-0/2019: $SNDX Syndax Pharmaceuticals provided 2019 clinical and corporate outlook -- data from ENCORE I/O combination program in melanoma and ovarian cancer expected in 1Q19. -- Go to this Pulse Post



01/-0/2019: $REGN Regeneron Pharma & Sanofi (SNY) restructure global Immuno-oncology Discovery and Development Agreement for new immuno-oncology cancer treatments. -- Go to this Pulse Post



01/-0/2019: $XBI Oncology stocks mostly lower after Bristol Myers (BMY) opts for attractively-valued cancer drug giant Celgene (CELG) in a $74B blockbuster deal. -- Go to this Pulse Post



01/-0/2019: $VCYT Veracyte entered strategic collaboration with Johnson & Johnson (JNJ) to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages, when the disease is most treatable. -- Go to this Pulse Post



01/-0/2019: $ATNX Athenex entered into a licensing and partnership agreement with Chongqing Jingdong Junzhuo Pharma to exclusively develop and commercialize KX2-391 for the treatment of actinic keratosis and oncology indications in humans in China. -- Go to this Pulse Post



01/-0/2019: $MRK Merck Keytruda received five new approvals in japan, including in advanced non-small cell lung cancer as adjuvant therapy for melanoma, and in advanced microsatellite instability-high tumors. -- Go to this Pulse Post



01/-0/2019: $LOXO Loxo Oncology leading oncology stocks higher after being acquired by Eli Lilly (LLY) for $8B at a 68% premium. -- Go to this Pulse Post



01/-0/2019: $LOXO Loxo Oncology up 65% leading oncology stocks higher after being acquired by Eli Lilly (LLY) for $8B in cash ($235 per share) at a 68% premium. -- Go to this Pulse Post



01/-0/2019: $SNDX Syndax Pharmaceuticals provided 2019 clinical and corporate outlook -- data from ENCORE I/O combination program in melanoma and ovarian cancer expected in 1Q19. -- Go to this Pulse Post



01/-0/2019: $REGN Regeneron Pharma & Sanofi (SNY) restructure global Immuno-oncology Discovery and Development Agreement for new immuno-oncology cancer treatments. -- Go to this Pulse Post



01/-0/2019: $XBI Oncology stocks mostly lower after Bristol Myers (BMY) opts for attractively-valued cancer drug giant Celgene (CELG) in a $74B blockbuster deal. -- Go to this Pulse Post



01/-0/2019: $VCYT Veracyte entered strategic collaboration with Johnson & Johnson (JNJ) to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages, when the disease is most treatable. -- Go to this Pulse Post



01/-0/2019: $ATNX Athenex entered into a licensing and partnership agreement with Chongqing Jingdong Junzhuo Pharma to exclusively develop and commercialize KX2-391 for the treatment of actinic keratosis and oncology indications in humans in China. -- Go to this Pulse Post



01/-0/2019: $MRK Merck Keytruda received five new approvals in japan, including in advanced non-small cell lung cancer as adjuvant therapy for melanoma, and in advanced microsatellite instability-high tumors. -- Go to this Pulse Post